Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Cytokinetics To Contact Him Directly To Discuss Their OptionsIf you suffered losses in Cytokinetics between December 27, 2023 and May 6, 2025 and would like to discuss your legal rig... Read more
Benzinga - Oct 08
Additional Data from MAPLE-HCM Shows Aficamten Improves Cardiac Structure and Function Compared to Metoprolol; Simultaneous Publication in the Journal of the American College of CardiologyNew Analysis Shows Annual Incidence Rate of Atrial Fibrillation with Aficamten is 1.5%, Consistent with Expec... Read more
Benzinga - Aug 31
Positive Trial Demonstrates Superiority of Aficamten to Standard-of-Care Beta-Blocker Metoprolol Primary Endpoint Result Consistent Across All Prespecified SubgroupsCompany to Host Investor Event and Webcast Tuesday September 2, 2025, at 8:00 AM Eastern TimeSOUTH SAN FRANCISCO, Calif., Aug. 30, 2... Read more
Benzinga - Aug 30
